Loading...
01/11 16:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A indicate strong financial performance, optimistic guidance, and strategic growth in key areas like energy and life sciences. The increase in dividends and share repurchases is a positive indicator for shareholder returns. Although there are concerns about headcount and long-term visibility, these are outweighed by positive growth metrics and strategic positioning. Given the market cap of $1.2 billion, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
Revenue Revenue increased by 10.8% year-over-year to $185.9 million. This growth reflects the durability of CRA's business model and was broad-based, with 7 of 11 practices growing year-over-year. Antitrust & Competition Economics, energy, finance, and intellectual property practices posted double-digit revenue growth. North American operations increased revenue by 6.8%, and international operations expanded 30.3% year-over-year, driven by Antitrust & Competition Economics and Life Sciences practices.
Profitability Non-GAAP net income, earnings per diluted share, and EBITDA increased by 12.7%, 16.4%, and 14.6%, respectively, year-over-year. This growth exceeded revenue growth and was driven by strong utilization and overall execution, with quarterly utilization reaching 77%.
Legal and Regulatory Services Revenue Revenue from CRA's legal and regulatory services increased 11.5% year-over-year. This growth was supported by activity in the broader legal market, including increased case filings and court judgments, merger-related activity, and demand for antitrust services.
Management Consulting Services Revenue Revenue increased 8% year-over-year, led by the energy practice and supported by the expansion in the Life Sciences practice. The energy practice contributed through initiatives like developing integrated resource plans and market design analysis, while the Life Sciences practice engaged in strategy for neurological assets and clinical trial design.
Capital Deployment Net cash outlays included $28.1 million to acquire and retain senior talent, $700,000 for capital expenditures, and $7.2 million returned to shareholders through dividends and share repurchases. The company announced a 16% increase in its quarterly cash dividend, supported by business growth and performance.
Consultant Headcount Consultant headcount ended at 968, a 1.0% year-over-year decrease compared to Q3 fiscal 2024, but a 3.3% sequential increase relative to Q2 fiscal 2025.
Antitrust & Competition Economics practice: Established a new high for quarterly revenue, supported high-profile mergers, and advised UnitedHealth Group on a $3.3 billion acquisition of Amedisys.
Intellectual Property practice: Advised on high-stakes litigation and valuation matters, including a patent infringement dispute related to mRNA COVID-19 vaccines, resulting in a $1.25 billion acquisition and $740 million payment to the client.
Energy practice: Supported a major California electric utility in developing its integrated resource plan and advised private capital clients on investments in energy infrastructure and digital infrastructure.
Life Sciences practice: Worked on strategy for a newly acquired portfolio of neurological assets, providing recommendations on clinical trial design and launch sequencing.
Geographic expansion: North American operations increased revenue by 6.8%, while international operations expanded by 30.3%, driven by Antitrust & Competition Economics and Life Sciences practices.
Legal and regulatory services: Revenue increased by 11.5%, supported by double-digit growth in case filings and court judgments.
Utilization rate: Achieved a quarterly utilization rate of 77%, contributing to profitability growth exceeding revenue growth.
Profitability: Non-GAAP net income, earnings per diluted share, and EBITDA increased by 12.7%, 16.4%, and 14.6%, respectively.
Revenue guidance: Raised revenue guidance for fiscal 2025 to $740 million-$748 million, up from $730 million-$745 million.
Dividend increase: Announced a 16% increase in quarterly cash dividend, reflecting confidence in business growth and performance.
Uncertain global macroeconomic, business, and political conditions: The company acknowledges that these factors can affect their business and their clients, posing risks to revenue and operational stability.
Regulatory and legal challenges: The company faces risks related to regulatory reviews and legal disputes, as evidenced by their involvement in high-profile cases such as the DOJ's review of UnitedHealth's acquisition and Microsoft's EU competition investigation.
Dependence on key practices and sectors: The company's strong performance is heavily reliant on specific practices like Antitrust & Competition Economics and sectors such as energy and life sciences. Any downturn in these areas could adversely impact overall performance.
High DSO (Days Sales Outstanding): The DSO stood at 115 days, which is relatively high and could indicate potential cash flow challenges or inefficiencies in receivables management.
Debt levels and financial obligations: The company has $95 million in borrowings under its revolving credit facility and net debt of $72.5 million, which could pose financial risks if not managed effectively.
Talent acquisition and retention costs: The company spent $28.1 million in the quarter to acquire and retain senior talent, which represents a significant expenditure and could impact profitability if not balanced with revenue growth.
Revenue Guidance: For full year fiscal 2025, CRA expects revenue in the range of $740 million to $748 million on a constant currency basis, an increase from the prior range of $730 million to $745 million.
Non-GAAP EBITDA Margin Guidance: CRA projects a non-GAAP EBITDA margin in the range of 12.6% to 13.0% for fiscal 2025, up from the prior range of 12.3% to 13.0%.
Macroeconomic and Business Conditions: CRA remains cautious about uncertain global macroeconomic, business, and political conditions that could impact its business and clients.
Dividend Payments: $3.2 million of dividend payments were made during the third quarter of 2025.
Increase in Quarterly Cash Dividend: A 16% increase in the quarterly cash dividend was announced, raising it from $0.49 to $0.57 per common share.
Historical Context of Dividend Growth: The new dividend amount is more than 4 times the size of the first dividend issued in 2016.
Share Repurchase Program: $4.0 million was spent on repurchasing approximately 22,000 shares at an average share price of $185.74 during the third quarter of 2025.
Remaining Share Repurchase Capacity: $10.9 million remains available under the share repurchase program.
The earnings call summary and Q&A indicate strong financial performance, optimistic guidance, and strategic growth in key areas like energy and life sciences. The increase in dividends and share repurchases is a positive indicator for shareholder returns. Although there are concerns about headcount and long-term visibility, these are outweighed by positive growth metrics and strategic positioning. Given the market cap of $1.2 billion, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
The earnings call shows a strong financial performance with revenue, net income, and EPS growth, but the market environment is volatile, and there are regulatory and supply chain challenges. The Q&A highlights uncertainties in guidance and restructuring details, impacting investor sentiment. The dividend payment supports shareholder value, but the overall mixed signals lead to a neutral outlook for stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
